Aspirin for primary prevention: a challenging decision.
作者信息
Pignone Michael
机构信息
Department of Medicine, University of North Carolina - Chapel Hill, Chapel Hill, NC (M.P.).
出版信息
J Am Heart Assoc. 2014 Aug 21;3(4):e001254. doi: 10.1161/JAHA.114.001254.
Abstract
摘要
相似文献
1
Aspirin for primary prevention: a challenging decision.
J Am Heart Assoc. 2014 Aug 21;3(4):e001254. doi: 10.1161/JAHA.114.001254.
2
Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease: Shared Decision Making in Clinical Practice.
JAMA. 2016 Aug 16;316(7):709-10. doi: 10.1001/jama.2016.8362.
3
Should patients stop taking aspirin for primary prevention?
Cleve Clin J Med. 2015 Feb;82(2):91-6. doi: 10.3949/ccjm.82a.14114.
4
Aspirin for the primary prevention of cardiovascular diseases.
Intern Emerg Med. 2012 Aug;7(4):375-9. doi: 10.1007/s11739-012-0791-z. Epub 2012 Jun 6.
5
Personalizing evidence-based primary prevention with aspirin: individualized risks and patient preference.
Circ Cardiovasc Qual Outcomes. 2011 May;4(3):260-2. doi: 10.1161/CIRCOUTCOMES.111.961136.
6
Aspirin in the primary prevention of vascular disease.
Lancet. 2009 Sep 12;374(9693):877; author reply 879. doi: 10.1016/S0140-6736(09)61620-2.
7
Aspirin for primary prevention: no. Author’s response.
J Prim Health Care. 2013;5(2):174.
8
Aspirin for primary prevention in the elderly.
Aging (Albany NY). 2019 Sep 6;11(17):6618-6619. doi: 10.18632/aging.102255.
9
Aspirin for the primary prevention of cardiovascular events: recommendations and rationale.
Am J Nurs. 2002 Mar;102(3):67, 69-70.
10
An Update on Aspirin for Cardioprevention: Implications for Patient Care.
J Fam Pract. 2021 Jan-Feb;70(1 suppl [i]):S1-S10. doi: 10.12788/jfp.0143.
引用本文的文献
1
The Protective Effect of Teprenone on Aspirin-Related Gastric Mucosal Injuries.
Gastroenterol Res Pract. 2019 Jun 18;2019:6532876. doi: 10.1155/2019/6532876. eCollection 2019.
本文引用的文献
1
Use of aspirin for primary and secondary cardiovascular disease prevention in the United States, 2011-2012.
J Am Heart Assoc. 2014 Jul 14;3(4):e000989. doi: 10.1161/JAHA.114.000989.
2
Measuring shared decision making: a review of constructs, measures, and opportunities for cardiovascular care.
Circ Cardiovasc Qual Outcomes. 2014 Jul;7(4):620-6. doi: 10.1161/CIRCOUTCOMES.113.000350. Epub 2014 May 27.
3
The effect of a decision aid intervention on decision making about coronary heart disease risk reduction: secondary analyses of a randomized trial.
BMC Med Inform Decis Mak. 2014 Feb 28;14:14. doi: 10.1186/1472-6947-14-14.
4
Executive summary: heart disease and stroke statistics--2014 update: a report from the American Heart Association.
Circulation. 2014 Jan 21;129(3):399-410. doi: 10.1161/01.cir.0000442015.53336.12.
5
How patient centered are medical decisions?: Results of a national survey.
JAMA Intern Med. 2013 Jul 8;173(13):1215-21. doi: 10.1001/jamainternmed.2013.6172.
6
Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials.
Am Heart J. 2011 Jul;162(1):115-24.e2. doi: 10.1016/j.ahj.2011.04.006.
7
Effect of aspirin on mortality in the primary prevention of cardiovascular disease.
Am J Med. 2011 Jul;124(7):621-9. doi: 10.1016/j.amjmed.2011.01.018. Epub 2011 May 17.
8
Don't use aspirin for primary prevention of cardiovascular disease.
BMJ. 2010 Apr 21;340:c1805. doi: 10.1136/bmj.c1805.
9
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.
Lancet. 2009 May 30;373(9678):1849-60. doi: 10.1016/S0140-6736(09)60503-1.
10
Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
Ann Intern Med. 2009 Mar 17;150(6):405-10. doi: 10.7326/0003-4819-150-6-200903170-00009.
Zotero 插件